ArticleKidney international reports2026
Metabolic Dysfunction-Associated Steatotic Liver Disease and Kidney Transplant Outcomes.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: We describe the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and evidence of advanced liver fibrosis by readily available noninvasive diagnostics and their implications to kidney transplant recipients (KTRs). Methods: In this retrospective cohort study of first-time KTRs (2008-2020), we assessed the prevalence and incidence of MASLD (hepatic steatosis on abdominal ultrasound alongside ≥ 1 cardiometabolic risk factors) and advanced hepatic fibrosis (Fibrosis-4 (FIB-4) index > 2.67). We fitted multivariable time-dependent Cox regression models to assess associations between MASLD and a composite of graft dysfunction (estimated glomerular filtration rate [eGFR] < 30 mL/min per 1.73 m Results: In 650 eligible KTRs (median age 57.2 [interquartile range {IQR}: 45.0-66.0] years, 34% female), prevalence per 100 KTR (95% confidence interval [CI]) at transplantation and 5-years post-transplant, was 21.7 (18.6-25.1) and 42.3 (38.5-46.2), respectively, for MASLD and 42.9 (39.1-46.8) and 69.7 (66.0-73.2), respectively, for advanced fibrosis. Incidence rate per 100 person-years was 5.5 (4.7-6.4) for MASLD and 2.2 (1.6-2.9) for advanced fibrosis in KTRs without MASLD and advanced fibrosis at transplantation, respectively. Adjusted hazard ratios (HR) for the composite, graft dysfunction, DCGF, and DWGF were 1.27 (0.98-1.65), 1.24 (0.86-1.78), 1.14 (0.75-1.73), and 1.56 (1.04-2.33) with versus without MASLD and 1.76 (1.14-2.71), 1.47 (0.71-3.01), 3.28 (1.78-6.06), and 1.68 (0.91-3.13) with FIB-4 > 2.67 versus FIB-4 < 1.3, respectively. Conclusion: KTRs with MASLD and advanced hepatic fibrosis demonstrate lower patient and graft survival, which could be amenable to timely interventions for cardiometabolic risk reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.